Lexicon Genetics Awarded Additional Grant for Study of Spinal Muscular Atrophy
Lexicon will receive $2.5 million in funding for the one-year extended term of the grant. The research program was initiated under a $2.0 million award to Lexicon. Lexicon has an agreement with the SMA Foundation for the potential development of drugs based on discoveries resulting from this program.
Spinal muscular atrophy is a genetic, motor-neuron disease characterized by the wasting of skeletal muscles. Caused by progressive degeneration of nerve cells in the spinal cord, the disease leads to increasing muscular weakness and atrophy and premature death due to respiratory problems.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.